TrialSignal transduction and targeted therapy2024

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.

Miao-Zhen Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.